Invesco Ltd. Increases Holdings in Artivion, Inc. $AORT

Key Points

• Invesco Ltd. increased its stake in Artivion, Inc. by 27.9%, now holding approximately $8.40 million worth of shares.
• Insider transactions were notable, with SVP Marshall S. Stanton and CEO James P. Mackin both selling shares, reducing their ownership percentages.
• Recent analyst reports have been largely positive, with upgrades to Artivion’s stock rating and target prices, reflecting an overall consensus rating of “Buy”.

Invesco Ltd. raised its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 27.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 341,656 shares of the company's stock after acquiring an additional 74,589 shares during the period. Invesco Ltd. owned approximately 0.80% of Artivion worth $8,398,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Legacy Advisors LLC bought a new stake in shares of Artivion in the 1st quarter worth $28,000. MCF Advisors LLC increased its holdings in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the 4th quarter worth $64,000. Raymond James Financial Inc. bought a new stake in shares of Artivion in the 4th quarter worth $275,000. Finally, Natixis Advisors LLC increased its holdings in shares of Artivion by 16.4% in the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock worth $310,000 after purchasing an additional 1,777 shares in the last quarter. Institutional investors own 86.37% of the company's stock.

Insider Buying and Selling

In other Artivion news, CEO James P. Mackin sold 12,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the business's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total value of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares of the company's stock, valued at $2,826,084. This represents a 22.09% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 115,990 shares of company stock worth $4,435,823. Company insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Oppenheimer reissued an "outperform" rating on shares of Artivion in a report on Friday, August 8th. LADENBURG THALM/SH SH lowered Artivion from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $32.00 to $38.80 in a report on Wednesday, August 13th. Wall Street Zen raised Artivion from a "hold" rating to a "buy" rating in a report on Monday, August 25th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Finally, JMP Securities lifted their price objective on Artivion from $33.00 to $42.00 and gave the stock a "market outperform" rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Artivion currently has a consensus rating of "Buy" and an average price target of $40.63.

Artivion Stock Performance

Shares of AORT traded up $0.06 during trading hours on Friday, hitting $43.87. The stock had a trading volume of 342,981 shares, compared to its average volume of 630,482. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The firm has a market capitalization of $2.07 billion, a PE ratio of -104.45 and a beta of 1.69. The stock has a fifty day moving average price of $35.07 and a 200 day moving average price of $29.31.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. The business's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.